For the latest COVID-19 Travel restrictions and recommendations please
click hereWith the recent pandemic highlighting the need for rapid drug discovery, AI has become an area of increased interest. This is driven by the ability to discover drugs through the use of machine and deep learning. The current challenges within the drug discovery industry include the significant time consumption and expenses involved. This conference will discuss the solutions to these problems with presentations and updates from leading industry experts.
AI in drug discovery is leading the way into a shorter, cheaper and more successful R&D era where compound generation is automated, drug synthesis is predictable and undruggable diseases are finally being targeted.
AI in drug discovery is becoming an integral part of the research and development area of treating diseases with more companies incorporating 'Big Data' and data scientists within their R&D teams. Although the
AI in drug discovery area has grown rapidly over the past few years, those in the industry acknowledge that there is a long way to go. Collaboration and partnerships are the key to driving this area forward.
Join us at our 3rd annual
AI in Drug Discovery conference and explore the latest industry updates in: the selection of targets using AI, decision making within drug discovery and closing the loop on
AI in drug discovery. Don't miss out on presentations from leaders within the field, giving insights into the latest industry advances and answering the big questions within
AI in Drug Discovery.
Benefits of Attending
- Discover the main topics of research within industry, with talks on decision making, target selection and closing the loop
- Engage with regulators about the guidance within machine learning and AI in Drug Discovery
- Learn about the new breakthroughs within clinical trials and the treatment of disease
- Explore the latest technologies in deep learning from leaders within the pharmaceutical industry
- Discuss the impact of big data and how it applies to AI drug discovery within Pharma
Who should attend
Key job titles include:
- Head of AI
- Head of Informatics
- Head of Data
- Head of Computational and Systems Toxicology
- Director/Head of Strategic Data & Digital
- Director/Head of Medicinal Chemistry
- Director/Head of Molecular Design
- Director/Head of Computational Chemistry
- Director/Head of Chemical Sciences
- Director of Therapeutic Technology
- Chief Information Scientist
- Chief Scientific Officer
- Principal Scientist (Computational/Medicinal Chemistry)
- Senior Application Scientist
- Senior Research Scientist
- Senior Bioinformatician
- Molecular Modelling Team Leader
- Data Team Leader
Plus Two Interactive Post-Conference Workshops | Wednesday 16th March 2022
Workshop A: From Drug Discovery to Healthcare, an AI insightJames Hodson, CEO, AI for Good Foundation
Senthujan Sen, Researcher, Applied AI Research, Sick Kids Childrens Hospital
Priyanka Challa, Sr. Analyst, Virtual Care Initiatives, CIHI
08.30 - 12.45
Workshop B: Deciphering AI Based Drug DiscoveryStephen Scott MacKinnon, Vice President of Research and Development, Research and Development, Cyclica
13.30 - 17.30
Featured 2022 Speakers Include:
- Akos Tarcsay, Product Manager, Chemaxon Ltd
- Alexander Hillisch, VP Head of Molecular Computational Design, Bayer AG
- Andrea Small-Howard, Chief Science Officer & Board Member, GB sciences
- Andrew Parton, Lead Data Scientist, Multiomic Health
- Andrew Pattison, Team Lead Digital Channels, World Health Organization (WHO)
- Bhupathy Alagiriswamy, Clinical Trial Manager, Boehringer Ingelheim
- Carl Poelking, Research Associate, Astex Pharmaceuticals
- Christian Tyrchan, Associate Director Computational Chemistry, AstraZeneca
- Darren Green, Director of Computational Chemistry, GSK
- Friedrich Rippmann, Director, Global Computational Chemistry & Biology, Merck
- Gabi Griffin, Lead Bioinformatics Scientist, Benevolent AI
- Gregory Vladimer, VP Translational Research, Exscientia
- Irene Choi, Senior Director, Verge Genomics
- James Arnold, Artificial intelligence and data science head finance, Genetech Inc
- James Hodson, CEO, AI for Good Foundation
- Kim Branson, SVP Global Head of AI and Machine Learning, GSK
- Maria Luisa Pineda, CEO and Co-Founder, Envisagenics
- Mathew Divine, Senior Data Scientist, Boehringer Ingelheim GmbH & Co. KG
- Matthew Segall, Chief Executive Officer, Optibrium
- Neil Thompson, Chief Scientific Officer, Healx Limited
- Peter Henstock, Machine Learning & AI Lead, Pfizer Global Pharmaceuticals
- Philipe Moingeon, Head of therapeutic area immuno-inflammation, Servier Pharmaceuticals
- Priyanka Challa, Sr. Analyst, CIHI
- Sandor Szalma, Global Head, Computational Biology, Takeda
- Senthujan Sen, Researcher, Sick Kids Childrens Hospital
- Varenka Angelica Rodriguez DiBlasi, Senior Scientist -Lab Head Exploratory Bioinformatics Group, Boehringer Ingelheim Pharmaceuticals, Inc.
Please fill in your name and email to receive the Conference Agenda of this event.
Venue
Hilton London Kensington
179-199 Holland Park Ave, Kensington, W11 4UL
London, UK
